Further analysis revealed that while CAR T therapy elicited no statistically significant endogenous anti-tumor CD8+ T-cell response and only a weak (but detectable) CD4+ T-cell response compared to untreated tumors, CAR-T combined with amph-ligand vaccination (hereafter, CAR T-vax) primed robust responses from both the CD4+ and CD8+ T-cell compartments (Figure 1C). The gene discussed is CD8A; the disease is neoplasm.